Skip to main content
Fig. 4 | Pediatric Rheumatology

Fig. 4

From: Reduction in the utilization of prednisone or methotrexate in Canadian claims data following initiation of etanercept in pediatric patients with juvenile idiopathic arthritis

Fig. 4

Average Weekly Doses of Etanercept by Age and Indication*. JIA, juvenile idiopathic arthritis. *Indications were inferred using an algorithm developed by IQVIA, which utilizes a patient’s drug history [7, 8, 30]. For psoriatic arthritis and ankylosing spondylitis indications, group sizes were less than 6 per age group. All indications refers to patients with a drug history representing juvenile idiopathic arthritis, psoriatic arthritis, or ankylosing spondylitis

Back to article page

Pediatric Rheumatology

ISSN: 1546-0096